Los puntos clave no están disponibles para este artículo en este momento.
The trial met its primary objective of noninferiority in AHV and further showed superiority of lonapegsomatropin compared to daily somatropin, with similar safety, in treatment-naïve children with GHD.
Thornton et al. (Sat,) studied this question.